GLP-1 and Body Composition: Why Tracking Muscle Mass, Body Fat, and Blood Pressure Matters Beyond Weight

When weight changes significantly, the number on the scale tells only part of the story. This is especially relevant for adults using GLP-1–based medications under medical supervision. Research on GLP-1 and body composition shows that weight loss can include changes in fat mass and lean tissues, making it useful to look beyond total pounds alone. Tracking body composition and cardiovascular measures such as blood pressure can provide additional context about how the body is changing over time, without replacing medical evaluation or treatment guidance.

Why Weight Alone Does Not Tell the Full Story

Body weight combines many different tissues and fluids into a single number. Two people at the same weight can have very different proportions of body fat, muscle, bone, and water.

That is why body composition tracking can add useful context. Key measurements may include:

• Body fat percentage: the estimated proportion of body weight that comes from fat.

• Skeletal muscle: muscle attached to the skeleton that supports movement and physical function.

• Fat-free mass: everything in the body that is not fat, including muscle, bone, organs, and body water.

• Body water percentage: an estimate of the proportion of the body made up of water.

• Visceral fat: fat located around internal organs.

One distinction matters especially: fat-free mass is not the same as skeletal muscle mass. OMRON’s body-composition materials make this distinction explicitly, which is important when interpreting changes during weight loss.

What Research Shows About GLP-1 and Body Composition

GLP-1–based therapies can produce substantial weight loss, but research shows that the change is not limited to body fat.

A 2026 systematic review and meta-analysis found reductions in adiposity during GLP-1–based therapy, while changes in muscle quantity varied across studies. Importantly, the authors concluded that current evidence is too limited and heterogeneous to make definitive claims about preservation or loss of skeletal muscle health. They also cautioned that reductions in lean mass should not automatically be interpreted as sarcopenia.

Source: Body Composition Remodeling During GLP-1-Based Therapy, 2026.

Another 2026 review of 20 randomized trials found that lean mass represented roughly 25%–39% of total weight lost with different incretin therapies, a proportion broadly comparable with lifestyle-based weight-loss interventions in the included studies.

The practical takeaway is not that GLP-1 medications “cause muscle loss.” It is that significant weight loss involves more than one body compartment, making trend tracking more informative than watching scale weight alone.

Why Tracking Body Composition Can Add Context

Tracking several measurements over time can help users see whether body changes are happening across fat, skeletal muscle, and other components.

The OMRON VIVA 360+ Smart Scale is designed specifically around this “beyond weight” approach. It tracks up to 18 body metrics, including body fat percentage, skeletal muscle, visceral fat level, body water percentage, bone mass, and fat-free mass. It also provides segmental analysis to show changes across different areas of the body.

Rather than reacting to a single measurement, look for patterns:

• Body weight trend

• Body fat percentage

• Skeletal muscle estimates

• Fat-free mass

• Visceral fat level

• Changes across body areas

VIVA 360+ uses full-body hand-to-foot bioelectrical impedance analysis and provides results in about 15 seconds. Measurements can sync with the OMRON Connect app to help users follow trends over time.

Why Blood Pressure Belongs in the Bigger Picture

Body composition tells you about body composition. It does not tell you your blood pressure.

Blood pressure remains a separate cardiovascular health measure, which is why a broader monitoring routine may include both a body composition device and an OMRON blood pressure monitor.

The 2025 AHA/ACC High Blood Pressure Guideline identifies home blood pressure monitoring as an important tool for improving blood pressure control when combined with standardized measurement and healthcare-team support.
 Source: American Heart Association ,  2025 High Blood Pressure Guideline.

Think of the roles separately:

• VIVA 360+: tracks body composition trends.

• Blood pressure monitor: tracks BP trends.

• Healthcare provider: interprets results and makes treatment decisions.

Common Mistakes When Tracking Changes During GLP-1 Use

More data can be useful, but only when it is interpreted correctly.

Avoid these common mistakes:

• Watching only scale weight: Body composition adds context.

• Calling all lean mass “muscle”: Lean or fat-free mass includes more than skeletal muscle.

• Reacting to one measurement: Follow trends over time.

• Using home data to adjust medication: Medication decisions belong to your healthcare provider.

• Comparing your numbers with someone else’s: Body composition varies between individuals.

• Ignoring blood pressure: Follow your provider’s recommendations for cardiovascular monitoring.

Quick Rules for Tracking More Than Weight

• Track trends rather than isolated readings.

• Separate total weight from body fat and skeletal muscle.

• Do not use “lean mass” and “muscle mass” interchangeably.

• Measure under similar conditions when possible.

• Include blood pressure if your healthcare provider recommends it.

• Discuss unexpected or significant changes with your care team.

• Use consumer monitoring tools for awareness, not diagnosis.

GLP-1–associated weight loss is about more than the number on the scale. Tracking body fat, skeletal muscle, fat-free mass, and blood pressure can provide a broader view of change over time. With tools such as OMRON VIVA 360+ and OMRON blood pressure monitors, users can follow meaningful trends while leaving medication and clinical decisions to their healthcare team.